Tagged with CAS

China DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021: from 34 new chemical drugs and 19 biological products in 2019 to 37 new chemical drugs and 24 biological products…

Brazil Although Brazil is one of the world’s top pharma markets, with the highest market value in Latin America, and has made major strides towards universal healthcare, the country continues to recover from its worst recession ever and the fallout from its disastrous COVID-19 response. Brazilian voters are preparing for a…

Americas Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the consolidation of its operations in the priority market of Mexico.   LatAm as a region offers many opportunities for innovation.…

Americas Two Big Pharma SVPs with responsibility for the entirety of Latin America weigh in on the management challenges inherent in LatAm and what they look for when appointing country managers in their region.   LatAm’s regional pharma market of USD 98 billion looks set to be the fastest growing in…

Mexico Mexico’s pharma market, the second largest in Latin America and among the top 15 globally, is set to top USD 13 billion in sales by 2028. Despite the encouraging numbers, some industry insiders are bemoaning the current government’s healthcare missteps along with the country’s low public spending and regulatory hurdles.…

LatAm A roundup of some of the latest from Latin American pharma, including India’s interest in the South American market, Bayer’s USD 361 million investment in Mexico, the EU’s partnership to boost investment in vaccines and drug production in the region, Panama’s cannabis strategy, and Brazil’s manufacturing attractiveness.   Indian pharma…

LatAm GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance of the country manager role, and explains how strong institutions make up for volatility in Latin America.   Five of…

Americas Boehringer Ingelheim’s managing director for South America, Dirk van Niekerk, provides an overview of the healthcare climate in South America, the challenges tied to political and economic instability, future opportunities in specialty care, and the company’s strategy to continue a decades-long legacy. With many new governments in the region, we…

USA While patient groups view the United States’ new Inflation Reduction Act as a positive move towards capping out-of-pocket drug costs for older Americans, the innovative pharma industry, after aggressively lobbying against it, still argues that the new legislation will hamper drug development. [The new law] is a significant step in…

USA Pharma companies have become vocal about social issues in recent years, championing access and affordability and launching initiatives to address diversity, but in the weeks since the United States’ Supreme Court’s overturn of the Roe v. Wade ruling on abortion the industry’s reaction has been far from consistent. While certain…

Canada Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the Public Health Agency of Canada’s recent smallpox contracts with Chimerix and Bavarian Nordic.   GSK flu vaccine deal renewal (Reuters)…

USA After US life expectancy fell for a second consecutive year, FDA Commissioner, Dr Robert M. Califf, speaking at the recent 2022 Biotechnology Innovation Organization (BIO22) International Convention, discussed what he believes to be the leading cause of death in the United States. Commissioner Califf stated during a fireside chat at…